Intralesional collagenase
Peyronie’s disease (PD)
acute phase
collagenase Clostridium histolyticum
Journal
Translational andrology and urology
ISSN: 2223-4691
Titre abrégé: Transl Androl Urol
Pays: China
ID NLM: 101581119
Informations de publication
Date de publication:
Aug 2022
Aug 2022
Historique:
received:
14
03
2022
accepted:
26
06
2022
entrez:
12
9
2022
pubmed:
13
9
2022
medline:
13
9
2022
Statut:
ppublish
Résumé
Peyronie's disease (PD) can be subdivided into acute and chronic phases. Intralesional collagenase All men receiving intralesional collagenase for PD from October 2015 through December 2020 at a single academic institution were retrospectively assessed for patient demographics and comorbidities, pre- and post-treatment curvature, and adverse events. Two definitions of acute phase were used: (I) acute phase duration ≤6 months, chronic phase duration >6 months; and (II) acute phase duration ≤12 months with penile pain, chronic phase duration >12 or no penile pain. Of 330 patients identified, 229 underwent intralesional collagenase treatment with pre- and post-treatment erect penile goniometry. 65 (28%) met criteria for definition 1 of acute phase, 37 (16%) met criteria for definition 2, and 76 (33%) met criteria for either. Percent change in penile curvature was not significantly different between acute and chronic phases using definition 1 (16.0% This single-center, retrospective cohort analysis suggests that intralesional collagenase is both safe and effective for the treatment of men with acute phase PD. Limitations exist inherent to retrospective review, since many men did not return for post-treatment goniometry, possibly skewing our cohort toward incomplete responders. Prospective, randomized studies will be required to confirm these findings.
Sections du résumé
Background
UNASSIGNED
Peyronie's disease (PD) can be subdivided into acute and chronic phases. Intralesional collagenase
Methods
UNASSIGNED
All men receiving intralesional collagenase for PD from October 2015 through December 2020 at a single academic institution were retrospectively assessed for patient demographics and comorbidities, pre- and post-treatment curvature, and adverse events. Two definitions of acute phase were used: (I) acute phase duration ≤6 months, chronic phase duration >6 months; and (II) acute phase duration ≤12 months with penile pain, chronic phase duration >12 or no penile pain.
Results
UNASSIGNED
Of 330 patients identified, 229 underwent intralesional collagenase treatment with pre- and post-treatment erect penile goniometry. 65 (28%) met criteria for definition 1 of acute phase, 37 (16%) met criteria for definition 2, and 76 (33%) met criteria for either. Percent change in penile curvature was not significantly different between acute and chronic phases using definition 1 (16.0%
Conclusions
UNASSIGNED
This single-center, retrospective cohort analysis suggests that intralesional collagenase is both safe and effective for the treatment of men with acute phase PD. Limitations exist inherent to retrospective review, since many men did not return for post-treatment goniometry, possibly skewing our cohort toward incomplete responders. Prospective, randomized studies will be required to confirm these findings.
Identifiants
pubmed: 36092841
doi: 10.21037/tau-22-188
pii: tau-11-08-1074
pmc: PMC9459553
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1074-1082Informations de copyright
2022 Translational Andrology and Urology. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tau.amegroups.com/article/view/10.21037/tau-22-188/coif). JNM is a consultant for Endo Pharmaceuticals, Incorporation, Boston Scientific Corporation, and Antares Pharma, Incorporation. AJS has received an investigator-initiated Publication Logistical Support Grant from Endo Pharmaceuticals, Incorporation. The other authors have no conflicts of interest to declare.
Références
J Sex Med. 2011 Dec;8(12):3446-51
pubmed: 21981553
Patient Prefer Adherence. 2017 Mar 02;11:431-448
pubmed: 28280315
Urology. 2017 Feb;100:125-130
pubmed: 27816605
J Sex Med. 2008 Sep;5(9):2179-84
pubmed: 18638001
Andrology. 2017 Jul;5(4):771-775
pubmed: 28718527
J Urol. 2004 Jul;172(1):259-62
pubmed: 15201789
J Sex Med. 2011 Feb;8(2):518-23
pubmed: 20955309
World J Mens Health. 2021 Jul;39(3):399-405
pubmed: 32648381
J Androl. 2011 Sep-Oct;32(5):502-8
pubmed: 21233397
Andrology. 2022 Jan;10(1):42-50
pubmed: 34297894
J Urol. 2015 Sep;194(3):745-53
pubmed: 26066402
Transl Androl Urol. 2018 Aug;7(4):603-617
pubmed: 30211050
Sex Med Rev. 2019 Apr;7(2):329-337
pubmed: 30503796
J Urol. 1993 Jan;149(1):56-8
pubmed: 8417217
J Urol. 2013 Jul;190(1):199-207
pubmed: 23376148
Adv Urol. 2011;2011:282503
pubmed: 22110491
PLoS One. 2016 Feb 23;11(2):e0150157
pubmed: 26907743
Urology. 2016 Aug;94:143-7
pubmed: 27211926
Transl Androl Urol. 2021 Feb;10(2):555-562
pubmed: 33718058
Sex Med Rev. 2021 Apr;9(2):340-349
pubmed: 32199788
J Urol. 2012 Jun;187(6):2268-74
pubmed: 22503048
World J Urol. 2020 Feb;38(2):269-277
pubmed: 31168744
J Urol. 2013 Aug;190(2):627-34
pubmed: 23376705
J Urol. 1990 Dec;144(6):1376-9
pubmed: 2231932
World J Urol. 2020 Feb;38(2):299-304
pubmed: 31093703
J Urol. 2006 Jun;175(6):2115-8; discussion 2118
pubmed: 16697815
J Sex Med. 2008 Aug;5(8):1985-90
pubmed: 18554257
Transl Androl Urol. 2013 Mar;2(1):39-44
pubmed: 26816722
World J Mens Health. 2021 Apr;39(2):352-357
pubmed: 32009312
World J Urol. 2020 Feb;38(2):293-298
pubmed: 31152197
J Sex Med. 2017 Oct;14(10):1220-1225
pubmed: 28874331
Res Rep Urol. 2016 Apr 29;8:61-70
pubmed: 27200305
Transl Androl Urol. 2021 Dec;10(12):4313-4319
pubmed: 35070813
BJU Int. 2015 Oct;116(4):650-6
pubmed: 25711400
Transl Androl Urol. 2020 Mar;9(Suppl 2):S269-S283
pubmed: 32257868
Urology. 2020 Nov;145:147-151
pubmed: 32777367